Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.
Shanghai Fosun Pharmaceutical announced that its subsidiary’s drug registration application for Luvometinib Tablets, intended for treating pediatric patients with Langerhans cell histiocytosis, has been accepted by China’s National Medical Products Administration and prioritized for review. This development signifies a strategic advancement for Fosun Pharma in expanding its drug offerings and strengthening its position in the pharmaceutical market, potentially impacting stakeholders positively by addressing unmet medical needs in pediatric care.
The most recent analyst rating on (HK:2196) stock is a Buy with a HK$35.30 price target. To see the full list of analyst forecasts on Shanghai Fosun Pharmaceutical (Group) Co stock, see the HK:2196 Stock Forecast page.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock company based in China, primarily involved in the pharmaceutical industry. The company focuses on the development and production of innovative drugs, with a market emphasis on providing treatments for various medical conditions.
Average Trading Volume: 7,872,547
Technical Sentiment Signal: Buy
Current Market Cap: HK$76.29B
For a thorough assessment of 2196 stock, go to TipRanks’ Stock Analysis page.